Ocular Therapeutix Inc
NASDAQ:OCUL
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.23
11.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OCUL stock under the Base Case scenario is 2.8 USD. Compared to the current market price of 8.83 USD, Ocular Therapeutix Inc is Overvalued by 68%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Ocular Therapeutix Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OCUL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Ocular Therapeutix Inc
Balance Sheet Decomposition
Ocular Therapeutix Inc
Current Assets | 473m |
Cash & Short-Term Investments | 427.2m |
Receivables | 30.2m |
Other Current Assets | 15.6m |
Non-Current Assets | 17.4m |
PP&E | 15.7m |
Other Non-Current Assets | 1.6m |
Current Liabilities | 36.4m |
Accounts Payable | 4m |
Accrued Liabilities | 32.2m |
Other Current Liabilities | 190k |
Non-Current Liabilities | 102m |
Long-Term Debt | 67.8m |
Other Non-Current Liabilities | 34.2m |
Earnings Waterfall
Ocular Therapeutix Inc
Revenue
|
61.4m
USD
|
Cost of Revenue
|
-5.8m
USD
|
Gross Profit
|
55.7m
USD
|
Operating Expenses
|
-196.9m
USD
|
Operating Income
|
-141.3m
USD
|
Other Expenses
|
-33.1m
USD
|
Net Income
|
-174.3m
USD
|
Free Cash Flow Analysis
Ocular Therapeutix Inc
USD | |
Free Cash Flow | USD |
OCUL Profitability Score
Profitability Due Diligence
Ocular Therapeutix Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Ocular Therapeutix Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
OCUL Solvency Score
Solvency Due Diligence
Ocular Therapeutix Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Ocular Therapeutix Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OCUL Price Targets Summary
Ocular Therapeutix Inc
According to Wall Street analysts, the average 1-year price target for OCUL is 18.59 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.
Dividends
Current shareholder yield for OCUL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
OCUL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2014-07-25. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.
Contact
IPO
Employees
Officers
The intrinsic value of one OCUL stock under the Base Case scenario is 2.8 USD.
Compared to the current market price of 8.83 USD, Ocular Therapeutix Inc is Overvalued by 68%.